← Leaderboards
Henry L Paulson
University Of Iowa
$29,880,294
Attributed
$38,572,701
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$66,216,820 · 20
By mechanism
P30$33,825,558 · 6
R01$14,333,450 · 4
U01$8,088,191 · 2
R35$5,356,529 · 1
T32$1,889,569 · 1
P01$1,642,835 · 1
Top collaborators
- Magdalena I Ivanova6 shared
- Tetsuo Ashizawa5 shared
- Alexandra Durr5 shared
- Thomas Klockgether5 shared
- Gulin Oz5 shared
- Dawn O Kleindorfer4 shared
- Hayley Sarah Mcloughlin4 shared
- Edgardo Rodriguez2 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNerve DegenerationNeurodegenerative DisordersSuccessProteinsLinkPathogenesisS DiseasePathway InteractionsNeuronsCollaborationsMouse ModelAffectMediatingFundingBrainPolyglutamineInnovationResearch PersonnelMutantResourcesQuality ControlMichiganTraining
Grant awards (99)
Michigan Alzheimer's Disease Research Center$3,441,683
P30 · FY2025 · AG · contact PI
Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways$1,087,708
R35 · FY2025 · NS · contact PI
Core A: Administrative Core$566,792
P30 · FY2025 · AG · contact PI
Training in Clinical and Basic Neuroscience$471,437
T32 · FY2025 · NS · contact PI
Michigan Alzheimer's Disease Research Center$3,437,554
P30 · FY2024 · AG · contact PI
Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways$1,055,075
R35 · FY2024 · NS · contact PI
Core A: Administrative Core$866,660
P30 · FY2024 · AG · contact PI
Training in Clinical and Basic Neuroscience$476,529
T32 · FY2024 · NS · contact PI
Michigan Alzheimer's Disease Research Center$3,574,378
P30 · FY2023 · AG · contact PI
Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways$1,087,708
R35 · FY2023 · NS · contact PI
Core A: Administrative Core$1,005,710
P30 · FY2023 · AG · contact PI
Michigan Alzheimer's Disease Research Center-Supplement$381,608
P30 · FY2023 · AG · contact PI
Core A: Administrative Core$381,608
P30 · FY2023 · AG · contact PI
Training in Clinical and Basic Neuroscience$295,239
T32 · FY2023 · NS · contact PI
Research Education Component$96,999
P30 · FY2023 · AG · contact PI
Michigan Alzheimer's Disease Research Center$3,075,904
P30 · FY2022 · AG · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,098,761
U01 · FY2022 · NS
Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways$1,087,708
R35 · FY2022 · NS · contact PI
Core A: Administrative Core$501,102
P30 · FY2022 · AG · contact PI
Michigan Alzheimerâs Disease Research Center-Supplement$500,223
P30 · FY2022 · AG · contact PI
Core A: Administrative Core$500,223
P30 · FY2022 · AG · contact PI
Research Education Component$96,999
P30 · FY2022 · AG · contact PI
Michigan Alzheimer's Disease Research Center$3,097,151
P30 · FY2021 · AG · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,220,506
U01 · FY2021 · NS
Mechanisms of neurodegenerative diseases: intersections with ubiquitin pathways$1,038,330
R35 · FY2021 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$486,330
U01 · FY2021 · NS
Core A: Administrative Core$484,516
P30 · FY2021 · AG · contact PI
Training in Clinical and Basic Neuroscience$416,152
T32 · FY2021 · NS · contact PI
Michigan Alzheimer's Disease Core Center$2,118,485
P30 · FY2020 · AG · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,221,189
U01 · FY2020 · NS
Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration$680,191
R01 · FY2020 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$552,105
U01 · FY2020 · NS
Core A: Administrative Core$403,134
P30 · FY2020 · AG · contact PI
Training in Clinical and Basic Neuroscience$230,212
T32 · FY2020 · NS · contact PI
Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration$156,000
R01 · FY2020 · NS · contact PI
Michigan Alzheimer's Disease Core Center$1,718,713
P30 · FY2019 · AG · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,183,360
U01 · FY2019 · NS
Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration$680,191
R01 · FY2019 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$547,957
R01 · FY2019 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$528,534
U01 · FY2019 · NS
Michigan Alzheimer's Disease Core Center$390,000
P30 · FY2019 · AG · contact PI
Michigan Alzheimer's Disease Core Center$390,000
P30 · FY2019 · AG · contact PI
Core A: Administrative Core$298,826
P30 · FY2019 · AG · contact PI
Michigan Alzheimer's Disease Core Center$1,709,226
P30 · FY2018 · AG · contact PI
Clinical Trial Readiness for SCA1 and SCA3$1,260,926
U01 · FY2018 · NS
Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration$695,691
R01 · FY2018 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$554,514
R01 · FY2018 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$536,480
U01 · FY2018 · NS
Michigan Alzheimer's Disease Core Center$390,000
P30 · FY2018 · AG · contact PI
Core A: Administrative Core$287,667
P30 · FY2018 · AG · contact PI
Michigan Alzheimer's Disease Core Center$1,700,024
P30 · FY2017 · AG · contact PI
Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration$611,077
R01 · FY2017 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$550,915
R01 · FY2017 · NS · contact PI
Core A: Administrative Core$403,536
P30 · FY2017 · AG · contact PI
Michigan Alzheimer's Disease Core Center$1,719,170
P30 · FY2016 · AG · contact PI
Integrating Quality Control: Studies of UBQLN2 in Age-Related Neurodegeneration$623,452
R01 · FY2016 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$547,314
R01 · FY2016 · NS · contact PI
Core A: Administrative Core$287,667
P30 · FY2016 · AG · contact PI
Investigating mechanisms of UBQLN2-mediated neurodegenerative disease$193,750
R21 · FY2016 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$532,511
R01 · FY2015 · NS · contact PI
Investigating mechanisms of UBQLN2-mediated neurodegenerative disease$232,500
R21 · FY2015 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$457,964
R01 · FY2014 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$445,776
R01 · FY2013 · NS · contact PI
Integrating Quality Control: Studies of CHIP in Age-related Neurodegeneration$277,580
R01 · FY2013 · AG · contact PI
Mechanisms of Polyglutamine Neurodegeneration$512,357
R01 · FY2012 · NS · contact PI
Integrating Quality Control: Studies of CHIP in Age-related Neurodegeneration$293,957
R01 · FY2012 · AG · contact PI
Development of a Knock-in Mouse Model for Spinocerebellar Ataxia Type 3$77,750
R03 · FY2012 · NS · contact PI
AIM 2012 Conference$10,000
R13 · FY2012 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$511,096
R01 · FY2011 · NS · contact PI
Integrating Quality Control: Studies of CHIP in Age-related Neurodegeneration$294,173
R01 · FY2011 · AG · contact PI
RNA interference as therapy for spinocerebellar ataxia type 3$189,038
R21 · FY2011 · NS · contact PI
Development of a Knock-in Mouse Model for Spinocerebellar Ataxia Type 3$77,750
R03 · FY2011 · NS · contact PI
AIM 2012 Conference$20,000
R13 · FY2011 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$527,466
R01 · FY2010 · NS · contact PI
Integrating Quality Control: Studies of CHIP in Age-related Neurodegeneration$306,266
R01 · FY2010 · AG · contact PI
RNA interference as therapy for spinocerebellar ataxia type 3$225,755
R21 · FY2010 · NS · contact PI
RNAi for Alzheimer's Disease$334,012
P01 · FY2009 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$320,671
R01 · FY2009 · NS · contact PI
Integrating Quality Control: Studies of CHIP in Age-related Neurodegeneration$309,575
R01 · FY2009 · AG · contact PI
RNAi for Alzheimer's Disease$344,433
P01 · FY2008 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$202,450
R01 · FY2008 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$54,151
R01 · FY2008 · NS · contact PI
RNAi for Alzheimer's Disease$345,006
P01 · FY2007 · NS · contact PI
Analysis of Fbx2 Family of Ubiquitin Ligases$321,711
R01 · FY2007 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$320,829
R01 · FY2007 · NS · contact PI
Analysis of Fbx2 Family of Ubiquitin Ligases$339,930
R01 · FY2006 · NS · contact PI
Mechanisms of Polyglutamine Neurodegeneration$330,489
R01 · FY2006 · NS · contact PI
RNAI for Alzheimer's Disease$306,911
P01 · FY2006 · NS · contact PI
Analysis of Fbx2 Family of Ubiquitin Ligases$339,397
R01 · FY2005 · NS
Mechanisms of Polyglutamine Neurodegeneration$336,278
R01 · FY2005 · NS
RNAI for Alzheimer's Disease$312,473
P01 · FY2005 · NS
Course Development in Neurobiology of Disease at the University of Iowa$54,145
R25 · FY2005 · MH
Analysis of Fbx2 Family of Ubiquitin Ligases$339,446
R01 · FY2004 · NS
MECHANISMS OF GLUTAMINE REPEAT NEURODEGENERATION$271,289
R01 · FY2004 · NS
MECHANISMS OF GLUTAMINE REPEAT NEURODEGENERATION$267,726
R01 · FY2003 · NS
MECHANISMS OF GLUTAMINE REPEAT NEURODEGENERATION$268,364
R01 · FY2002 · NS
MECHANISMS OF GLUTAMINE REPEAT NEURODEGENERATION$260,723
R01 · FY2001 · NS
MECHANISMS OF GLUTAMINE REPEAT NEURODEGENERATION$241,039
R01 · FY2000 · NS
MECHANISMS OF GLUTAMINE REPEAT NEURODEGENERATION$2,934
R01 · FY2000 · NS